norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study

Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer A, Spreda F, Kluwe J, Petersen J, Boettler T, Halilbasic E, Greinwald R, Proels M, Manns MP, Fickert P, Trauner MH (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Hepatology Wiley-Blackwell

Book Volume: 66

Pages Range: 106A-107A

Authors with CRIS profile

Andreas Kremer Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Medizinische Universität Wien AT Austria (AT) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Asklepios Kliniken DE Germany (DE) Julius-Maximilians-Universität Würzburg DE Germany (DE) Dr. Falk Pharma GmbH DE Germany (DE) Universität Leipzig DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Albert-Ludwigs-Universität Freiburg DE Germany (DE) Universität zu Köln DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite

APA:

Traussnigg, S., Schattenberg, J.M., Demir, M., Wiegand, J., Geier, A., Teuber, G.,... Trauner, M.H. (2017). norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study. (pp. 106A-107A).

MLA:

Traussnigg, Stefan, et al. "norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study." 2017. 106A-107A.

BibTeX: Download